细胞凋亡
癌症研究
头颈部鳞状细胞癌
类有机物
基底细胞
化学
细胞
细胞生长
机制(生物学)
药品
细胞培养
细胞内
抑制器
顺铂
医学
癌症
细胞存活
癌
候选药物
内科学
间充质干细胞
舌头
作者
X. Z. Li,Lin Chen,Jian Meng,B Chen,Chen Du
标识
DOI:10.2174/0115680096393765251030065019
摘要
INTRODUCTION: Tongue Squamous Cell Carcinoma (TSCC) is a prevalent head and neck malignancy with limited targeted therapies and minimal toxicity. Sodium Cantharidate (SCA), a natural compound, exhibits anti-tumor potential, but its molecular targets in TSCC remain undefined. This study aimed to evaluate SCA's anti-TSCC efficacy in preclinical models and elucidate its mechanism of action. METHODS: SCA's effects on TSCC cells were assessed using CCK-8 viability, scratch wound healing, Transwell migration/invasion, and flow cytometry (apoptosis). Efficacy was further evaluated in nude mouse xenograft models and patient-derived TSCC organoids. Molecular mechanisms were investigated via Western blotting. RESULTS: SCA significantly inhibited TSCC cell proliferation, migration, and invasion, and induced dose-dependent apoptosis in vitro. It demonstrated cytotoxicity in xenografts and organoids. Western blotting showed SCA upregulated p53 protein and phosphorylation at Ser33, Ser37, and Ser46. Pro-apoptotic BAX and cleaved Caspase 3 increased, while anti-apoptotic BCL-2 decreased, significantly lowering the BCL-2/BAX ratio. DISCUSSION: SCA attenuates TSCC growth and invasion in vitro and in vivo, primarily by inducing apoptosis through modulation of p53 phosphorylation. This is the first study to validate SCA's efficacy using patient-derived TSCC organoids, highlighting their value for pre-clinical drug assessment. While promising, further mechanistic depth is warranted. The results support SCA's potential for clinical translation. CONCLUSION: SCA potently inhibits TSCC progression in cell lines, xenografts, and patient-derived organoids. Its mechanism involves activation of p53 phosphorylation, shifting the BCL-2/BAX balance, and triggering caspase-dependent apoptosis. These findings position SCA as a promising therapeutic candidate and underscore the utility of organoid models in oncology drug development.
科研通智能强力驱动
Strongly Powered by AbleSci AI